论文部分内容阅读
抗体药物偶联物(antibody drug conjugates,ADC)是一类具有良好靶向性的抗肿瘤药物,它利用单克隆抗体与高效细胞毒分子的完美结合,最大程度地增加了高效细胞毒分子的治疗窗。近年来,随着Adcetris和Kadcyla两个ADC药物的相继上市,抗体药物偶联物的研究也逐渐成为靶向抗肿瘤治疗领域的一个研究热点。本文对ADC主要组成部件研究进展及上市ADC药物Kadcyla和美登素相关ADC药物的临床试验状况进行综述,并对未来ADC发展趋势进行展望,希望为今后的ADC药物研究工作提供的参考和借鉴。
Antibody drug conjugates (ADCs) are a class of well-targeted antitumor drugs that utilize the perfect combination of monoclonal antibodies with highly effective cytotoxic molecules to maximize the treatment of highly effective cytotoxic molecules window. In recent years, with the advent of two ADC drugs, such as Adcetris and Kadcyla, the study of antibody drug conjugates has gradually become a research hotspot in the field of anti-tumor therapy. This review summarizes the research progress of the major components of ADC and the clinical trial status of listed ADC drugs Kadcyla and maytansine-related ADC drugs, and looks forward to the development trend of ADC in the future, hoping to provide reference and reference for future ADC drug research.